

5th Annual Drug Delivery Systems Conference

Assessing Innovations in Drug Delivery Technologies and Evaluating Business Models

9th-11th February 2010, BSG Conference Centre, London, UK

Key Speakers:

- Dr. Sven Stegemann, Director, **Pfizer**
- Norbert Rasenack, Fellow Inhalation Development, **Novartis**
- Dr. Jan Möschwitzer, Head Early Pharmaceutical Development, **Solvay**
- Dr. Oliver Steinbach, Department Head, **Philips Research Laboratories**
- Joel Richard, Senior Director, Head of Drug Product Development, **Ipsen**
- Dr. Duncan F Rogers, Reader, National Heart and Lung Institute, **Imperial College London**
- Dr. Dejan Djuric, R&D Project Management Excipients, **BASF**
- Dr. Cheryl Barton, Managing Director, **Pharmavision**
- Gerry Kamstra, Partner, IP & Life Sciences, **Bird and Bird**
- Prof. Marc Brown, CSO, **MedPharm**
- Craig Thomson, Attorney, **Murgitroyd & Company**
- Dr. Giuseppe Battaglia, Lecturer in Bionanotechnology, **University of Sheffield**
- Dr. Piet Christiaens, Scientific Director, **Toxikon Europe**
- Dr Pierandrea Esposito, Associate Director, **SiTec PharmaBio**

Conference Agenda

Day One, Wednesday 10th February 2010

09:30 Registration and refreshments

10:00 Opening address from the chair

10:10 Analysing key trends in the field of drug delivery

- Impact of emerging drug delivery technologies on the pharmaceutical industry
- Evaluating the latest market developments

10:50 Innovations in trans (dermal) drug delivery

- Issues of drug delivery to the skin
- Past successes and failures (trans) dermal drug delivery
- Innovations in active and passive methods of (trans) dermal drug delivery
- Gene delivery; the final frontier

Dr Marc Brown

Chief Technology Officer

MedPharm

11:30 Morning refreshments

11:50 Drug delivery systems for oncology products

- Cancer market context and expectations
- Key challenges for delivery of oncology products
- Oral chemotherapy: opportunities, challenges and delivery solutions
 - Drug permeation and bioavailability enhancement
 - Delivery strategies based on nanosystems and lipid-based formulations
- I.v. oncology products: challenges and delivery solutions
 - Drug solubilisation
 - Modification of biodistribution and toxicology profile of drugs
 - Delivery strategies based on nanosystems for small molecules and oligonucleotides

- Subcutaneous oncology products: challenges and delivery solutions
- Sustained-release formulations of peptides
- Perspectives for new s.c. formulations of proteins and mAbs

Joel Richard

**Senior Director, Head of Drug Product Development
Ipsen**

12:30 Particle engineering as contributor to a successful pharmaceutical drug product development - challenges, opportunities, trends

- Poorly soluble
- Inhalation delivery systems
- Technologies: opportunities and drawbacks

Norbert Rasenack

**Fellow Inhalation Development
Novartis**

13:10 Networking lunch

14:30 Stem cell-based therapeutic delivery: challenges & opportunities

- Ethical debates and funding, immune rejection, cancerous potential and issues surrounding the manufacture of stable, pure cell therapeutics
- Delivery of stem cells for CNS disorders
- Autologous products, derived from a patient's own tissue, will be the first to reach the market

Dr Cheryl L Barton

**Managing Director
Pharmavision**

Dr Sara Sleigh

**Senior Associate
Pharmavision**

15:10 Gatecrashing the cell

- Why it is important to deliver within cells' cytosol
- Biomimetic strategies for cytosolic delivery
- Delivery of DNA, siRNA, ODN, mRNA and their therapeutic implications
- Delivery of contrast agent and how cytosolic delivery can revolutionise diagnostics
- New therapeutic approaches based on cytosolic delivery

Dr Giuseppe Battaglia

**Biomaterials and Tissue Engineering Group
University of Sheffield**

15:50 Afternoon refreshments

16:10 Challenges and opportunities in the delivery of small molecules and of biotherapeutics

- Drug delivery role in new drugs development and in lifecycle management
- Trends and changes in delivery of therapeutic biomolecules
- Current issues in small molecules delivery
- New formulation technologies or molecular engineering?

Dr. Pierandrea Esposito

**Associate Director
SiTec PharmaBio**

16:50 Future therapeutic targets for respiratory disease

- Incidence and economic burden of asthma and chronic obstructive pulmonary disease (COPD)
- Overview of pathophysiology of asthma and COPD
- Overview of strategies for target identification and novel drug development

- Options for improving existing pharmacotherapy
- Hypothesis-driven novel targets
- Natural products, 'phytoceuticals' and non-synthetics
- Assessment of clinical trial progression of new drugs

Dr. Duncan F Rogers
Reader, National Heart and Lung Institute
Imperial College London

17:40 Closing remarks from the chair

17:30 Networking Drinks

Take your discussions further and build new relationships in a relaxed and informal setting

Day two, Thursday 11th February 2010

09:30 Registration and refreshments

10:00 Opening address from the chair

10:10 Design drug delivery for individual patient populations

- Changing patient population and its relevance for therapy
- Individualisation of drug delivery in development and manufacturing
- Drug delivery for effective medication management
- Drug delivery aligning technology with patient needs

Dr. Sven Stegemann
Director
Pfizer

10:50 Image-guided ultrasound- triggered drug delivery

- Use of drug loaded, temperature (liposomes) and pressure sensitive (microbubbles) systems for ultrasound triggered drug delivery
- Tracking, monitoring and quantifying drug release with ultrasound or MRI through the incorporation of imaging labels in drug carriers
- Formulations and applications for different drug formats: small molecules, biologics, nucleic-acid based therapeutics
- Examples from different disease areas.g. oncology, cardiology, metabolic diseases

Dr. Oliver Steinbach
Department Head
Philips Research Laboratories

11:30 Morning refreshments

11:50 Drug nanocrystals prepared by using different particle size reduction methods

- Overview of particles size reduction technologies used in academia and industry, bottom-up, top-down and combinative processes
- When can API nanonisation helps to improve the bioavailability of poorly soluble compounds
- Aspects to be considered during development: stabilisation, analysis and solidification
- The use of nanonised API at different stages of development
- Case study

Dr. Jan Möschwitzer
Head Early Pharmaceutical Development,
Solvay

12:30 Regulatory Requirements for Biocompatibility Testing of Drug Delivery Devices

- Classification of a Drug Delivery Device: Is the product a Drug or a Device?
- General Considerations regarding Biocompatibility testing
- Typical Biocompatibility Tests to be considered
- Testing/Documentation requirements for the submission of a Medical Device
- Testing/Documentation requirements for the submission of a Medicinal Product/Pharmaceutical Container

Dr. Piet Christiaens
Scientific Director
Toxikon Europe

13:10 Networking lunch

14:30 Drug synthesis and delivery IP due diligence

- Importance of IP protecting manufacturing process and drug delivery technology in late stage investments
- Typical issues around manufacturing process patents
- Typical issues around drug delivery patents
- Subsistence of Supplementary Protection Certificates
- Regulatory Data Protection and Orphan Drug
- Protection in late stage investments

Gerry Kamstra

**Partner, IP & Life Sciences
Bird and Bird**

15:10 Ensuring collaborations enhance rather than stifle exploitation of new technology

- Problems associated with not addressing ownership of IP early in collaboration
- How the law can help to avoid these problems
- Is there any reason to share IP?
- Examination of collaboration case studies

Craig Thomson

**Attorney
Murgitroyd & Company**

15:50 Afternoon refreshments

16:10 Polymeric Solubilizer for Hot Melt Extrusion

- Characterization of a bifunctional polymer which is capable of solubilization and of forming solid solutions with poorly soluble drugs
- Manufacturing of solid solutions
- Applications for polymeric solubilizers
- Solubility and Bioavailability enhancement

Dr. Dejan Djuric

**R&D Project Management Excipients
BASF**

16:50 Presentation to be announced

17:30 Chair's closing remarks

17:40 End of Conference

-Pricing-

**Standard Rate for 2 day Conference-
£1299 + VAT:£194.85 = Total:£1493.85**

**Academic & Health Care Organisations Rate for 2 day conference-
£899 + VAT:£134.85 = Total:£1033.85**

- If you would like to send more than 1 person then take advantage of the 3 for 2 offer. Send 3 people but only pay for 2.

- How to book -

Booking is simple! All you need to register is contact Bijal.

You can either call me on TEL:+44(0)2075499946

or email:bijal.patel@vgpharma.com

Please feel free to contact me should you have any questions, I look forward to hearing from you.

*Kind Regards,
Bijal Patel*